Search
forLearn
5 / 801 resultslearn Pronalen Fibro-Actif
learn PTT-6®
learn Epidermal Growth Factor
learn PTD-DBM
Research
5 / 1000+ results
research Pannexin 3 regulates skin development via Epiprofin
Pannexin 3 helps skin and hair growth by controlling a protein called Epiprofin.
research Molecular mechanism for transcriptional regulation of the parathyroid hormone gene by Epiprofin
Epiprofin suppresses parathyroid hormone gene activity, helping regulate calcium levels and could be a treatment target for hyperparathyroidism.
research Eosinophilic pustular folliculitis (Ofuji’s disease) without macroscopic pustules
EPF can occur without visible pustules.
research Tooth Regeneration: Insights from Tooth Development and Spatial-Temporal Control of Bioactive Drug Release
Tooth regeneration could become possible by controlling how and when bioactive factors are released.
research An observational analysis of erythromelanosis follicularis faciei et colli
EFFC might be common but underreported.
Community Join
5 / 1000+ resultscommunity The PP405 news are the best news we've had in the last 20 or more years.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community is there any news about pp405 please
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.